Takeda Pharmaceutical (NYSE:TAK) Downgraded to Buy Rating by Wall Street Zen
Wall Street Zen lowered Takeda Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday...
MarketBeat·1d ago
More News
200,033 Shares in Takeda Pharmaceutical Co. $TAK Acquired by XY Capital Ltd
XY Capital Ltd bought a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission...
MarketBeat·8d ago
Takeda Pharmaceutical Co. $TAK Shares Sold by Van ECK Associates Corp
Van ECK Associates Corp cut its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 12.7% in the 3rd quarter, according to the company in its most recent filing with the...
MarketBeat·9d ago
Capital Research Global Investors Buys 108,556 Shares of Takeda Pharmaceutical Co. $TAK
Capital Research Global Investors increased its stake in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 0.8% during the 3rd quarter, according to its most recent disclosure with the Securities...
MarketBeat·10d ago
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
DNLI stock jumps as investors eye an April 5, 2026, FDA decision on tividenofusp alfa for Hunter syndrome, a key catalyst for growth.
Zacks·11d ago
Fisher Asset Management LLC Lowers Stock Position in Takeda Pharmaceutical Co. $TAK
Fisher Asset Management LLC lessened its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 59.0% during the 3rd quarter, according to the company in its most recent...
MarketBeat·14d ago
Takeda Pharmaceutical (NYSE:TAK) Upgraded by Zacks Research to "Hold" Rating
Zacks Research upgraded shares of Takeda Pharmaceutical from a "strong sell" rating to a "hold" rating in a research report on Tuesday...
MarketBeat·17d ago
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (Protagonist) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and...
Business Wire·20d ago
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
Denali posts narrower-than-expected Q4 loss as FDA extends review of tividenofusp alfa, with $966M cash backing pipeline advances and no Q4 revenues.